ES2193406T3 - Composiciones y metodos para mejorar la funcion intestinal. - Google Patents
Composiciones y metodos para mejorar la funcion intestinal.Info
- Publication number
- ES2193406T3 ES2193406T3 ES97946986T ES97946986T ES2193406T3 ES 2193406 T3 ES2193406 T3 ES 2193406T3 ES 97946986 T ES97946986 T ES 97946986T ES 97946986 T ES97946986 T ES 97946986T ES 2193406 T3 ES2193406 T3 ES 2193406T3
- Authority
- ES
- Spain
- Prior art keywords
- compositions
- methods
- lpg
- intestinal function
- improve intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000003871 intestinal function Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000000936 intestine Anatomy 0.000 abstract 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
EL GLP - 2 ESTIMULA EL CRECIMIENTO DEL TEJIDO TANTO DEL INTESTINO DELGADO COMO DEL INTESTINO GRUESO, CUANDO SE ADMINISTRA JUNTO CON OTROS AGENTES. LA INVENCION PROPORCIONA COMPOSICIONES FARMACEUTICAS DE GLP - 2 CON AL MENOS OTRO AGENTE QUE AUMENTE LA ACTIVIDAD BIOLOGICA DEL GLP - 2, PROCEDIMIENTOS PARA FOMENTAR EL CRECIMIENTO DEL TEJIDO TANTO DEL INTESTINO DELGADO COMO DEL GRUESO, Y PARA MEJORAR LOS TRASTORNOS NUTRICIONALES O GASTROINTESTINALES, GRACIAS A UN AUMENTO DE LOS NIVELES SERICOS DE GLP - 2 Y AL MENOS OTRO AGENTE, DESCRIBIENDOSE TAMBIEN KITS PARA LLEVAR A LA PRACTICA LOS PROCEDIMIENTOS DE LA INVENCION.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/763,177 US5952301A (en) | 1996-12-10 | 1996-12-10 | Compositions and methods for enhancing intestinal function |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2193406T3 true ES2193406T3 (es) | 2003-11-01 |
Family
ID=25067085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97946986T Expired - Lifetime ES2193406T3 (es) | 1996-12-10 | 1997-12-10 | Composiciones y metodos para mejorar la funcion intestinal. |
Country Status (10)
Country | Link |
---|---|
US (1) | US5952301A (es) |
EP (1) | EP0944396B1 (es) |
AT (1) | ATE233096T1 (es) |
AU (1) | AU5220098A (es) |
CA (1) | CA2274596C (es) |
DE (1) | DE69719360T2 (es) |
DK (1) | DK0944396T3 (es) |
ES (1) | ES2193406T3 (es) |
PT (1) | PT944396E (es) |
WO (1) | WO1998025644A1 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020025933A1 (en) * | 1996-08-30 | 2002-02-28 | Knudsen Liselotte Bjerre | GLP-2 derivatives |
CA2236519C (en) | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
ATE253375T1 (de) * | 1997-05-16 | 2003-11-15 | Ontario Inc 1149336 | Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes |
EP2583675A1 (en) * | 1998-02-02 | 2013-04-24 | Trustees Of Tufts College | Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism |
WO1999058144A1 (en) * | 1998-05-11 | 1999-11-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
CA2339537A1 (en) * | 1998-08-21 | 2000-03-02 | Barbara Wallner | Regulation of substrate activity |
US6979697B1 (en) | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
GB9906715D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for promoting growth |
GB9906714D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for improving fertility |
EP1187619A1 (en) * | 1999-05-25 | 2002-03-20 | Point Therapeutics, Inc. | Anti-tumor agents comprising boroproline compounds |
EP1806138A1 (en) * | 1999-05-25 | 2007-07-11 | Point Therapeutics, Inc. | Anti-tumor agents comprising boroproline compounds |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
DE60037535D1 (de) * | 1999-11-03 | 2008-01-31 | Novo Nordisk As | Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion |
WO2001032199A1 (en) | 1999-11-05 | 2001-05-10 | Rogoff Joseph A | Secretin and secretin pharmaceuticals for treating lactose intolerance |
GB9930882D0 (en) * | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
US20070135345A1 (en) * | 2000-09-18 | 2007-06-14 | Henriksen Dennis B | Use of GLP-2 for the treatment or prevention, of bone-related disorders |
US7371721B2 (en) * | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
EP1970072A1 (en) | 2000-09-18 | 2008-09-17 | Sanos Bioscience A/S | Use of GLP-2 peptides for the treatment of hyperparathyroidism |
US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
DK1360202T3 (da) * | 2001-02-16 | 2008-09-22 | Conjuchem Biotechnologies Inc | Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser |
CA2466870A1 (en) * | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Methods for treating autoimmune disorders, and reagents related thereto |
CA2468192A1 (en) * | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
US20040038864A1 (en) * | 2002-06-27 | 2004-02-26 | Per Balschmidt | Use of dimethyl sulfone as isotonicity agent |
WO2004035624A2 (en) * | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
US20050026859A1 (en) * | 2002-11-12 | 2005-02-03 | John Hilfinger | Methods and compositions of gene delivery agents for systemic and local therapy |
US20080026077A1 (en) * | 2002-11-12 | 2008-01-31 | John Hilfinger | Methods and compositions of gene delivery agents for systemic and local therapy |
US7576121B2 (en) * | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
PT1689757E (pt) * | 2003-11-12 | 2014-12-09 | Sino Med Internat Alliance Inc | Compostos heterocíclicos de ácido borónico |
US7767828B2 (en) * | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7317109B2 (en) * | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
BRPI0513384A (pt) * | 2004-07-14 | 2008-05-06 | Novartis Ag | combinação de inibidores de dpp-iv e compostos que modulam receptores de 5-ht3 e/ou 5-ht4 |
ATE498631T1 (de) * | 2005-05-04 | 2011-03-15 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
US7825139B2 (en) * | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
KR101527233B1 (ko) | 2006-11-08 | 2015-06-08 | 질랜드 파마 에이/에스 | 선택적인 글루카곤 유사 펩티드-2(glp-2) 유사체 |
US20110295151A1 (en) * | 2010-05-26 | 2011-12-01 | Bakos Gregory J | Enteroendocrine Manipulation for Metabolic Effect |
TR201802689T4 (tr) | 2012-05-03 | 2018-03-21 | Zealand Pharma As | Glukagon benzeri peptit-2 (glp-2) analogları. |
ES2913946T3 (es) | 2013-07-08 | 2022-06-06 | The Univ Of Utah Research Foundation | Péptido y su uso en el tratamiento de trastornos inflamatorios |
CN106167789B (zh) * | 2015-05-21 | 2020-08-04 | 中国科学院上海营养与健康研究所 | 低氧处理的间充质干细胞及其应用 |
CN106589110B (zh) * | 2015-10-15 | 2020-01-17 | 上海迈迹生物医药科技有限公司 | 包含聚合物和glp-2衍生物的缀合物 |
DK3551651T3 (da) | 2016-12-09 | 2024-05-13 | Zealand Pharma As | Acylerede glp-1/glp-2-dobbeltagonister |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2174838T3 (es) * | 1991-10-07 | 2002-11-16 | Brigham & Womens Hospital | Metodo para aumentar la absorcion del intestino. |
NZ243071A (en) * | 1992-06-08 | 1994-09-27 | Kabi Pharmacia Ab | Igf-2 (or analogue) compositions for pharmaceutical uses |
US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
EP2218734B1 (en) * | 1996-04-12 | 2013-06-05 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
-
1996
- 1996-12-10 US US08/763,177 patent/US5952301A/en not_active Expired - Lifetime
-
1997
- 1997-12-10 DK DK97946986T patent/DK0944396T3/da active
- 1997-12-10 AU AU52200/98A patent/AU5220098A/en not_active Abandoned
- 1997-12-10 AT AT97946986T patent/ATE233096T1/de active
- 1997-12-10 CA CA002274596A patent/CA2274596C/en not_active Expired - Fee Related
- 1997-12-10 PT PT97946986T patent/PT944396E/pt unknown
- 1997-12-10 ES ES97946986T patent/ES2193406T3/es not_active Expired - Lifetime
- 1997-12-10 EP EP97946986A patent/EP0944396B1/en not_active Expired - Lifetime
- 1997-12-10 DE DE69719360T patent/DE69719360T2/de not_active Expired - Lifetime
- 1997-12-10 WO PCT/CA1997/000945 patent/WO1998025644A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CA2274596C (en) | 2004-11-09 |
EP0944396B1 (en) | 2003-02-26 |
DE69719360D1 (de) | 2003-04-03 |
DE69719360T2 (de) | 2003-12-04 |
AU5220098A (en) | 1998-07-03 |
US5952301A (en) | 1999-09-14 |
WO1998025644A1 (en) | 1998-06-18 |
PT944396E (pt) | 2003-07-31 |
CA2274596A1 (en) | 1998-06-18 |
EP0944396A1 (en) | 1999-09-29 |
ATE233096T1 (de) | 2003-03-15 |
DK0944396T3 (da) | 2003-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2193406T3 (es) | Composiciones y metodos para mejorar la funcion intestinal. | |
ES2179351T3 (es) | Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores. | |
BR9910251A (pt) | Estimulação hematopoiética | |
ES2163034T3 (es) | Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana. | |
BR0110091A (pt) | Composições e processos para terapia e diagnóstico de câncer de mama | |
UY24805A1 (es) | Peptidos y compuestos que se enlazan al receptor de la trombopoyetina | |
ES2175460T3 (es) | Compuesto de lipoxinas y su utilizacion en el tratamiento de patologias con proliferacion celular. | |
EA199901107A1 (ru) | Системы и устройства для лечения переломов костей или больных костей с помощью расширяемых тел (варианты), стерильный набор инструментов для введения в кость (варианты) | |
DK124091D0 (da) | Farmaceutisk genprodukt | |
ES2120274T3 (es) | Utilizacion de un extracto de una bacteria filamentosa no fotosintetica y composicion. | |
ES2181725T3 (es) | Inhibidores de hiv proteasa. | |
BR0103256A (pt) | Utilização de substâncias bioquìmicas para uma composição para a prevenção e tratamento de condições de saúde causadas por constrição de células de músculo liso em órgãos do corpo humano | |
ES2035847T3 (es) | Un procedimiento para la elaboracion de una preparacion farmaceutica. | |
CR9879A (es) | Moduladores de ccr5 (divisional de la solicitud n° 6392) | |
ES2153034T3 (es) | Sistema de suministro en microparticulas. | |
CO4770978A1 (es) | Empleo de epinastina para el tratamiento de dolores | |
ES2040727T3 (es) | Un proceso para preparar una formulacion en aerosol en solucion de un analogo. | |
FR2591485B1 (fr) | Compositions stabilisees contenant l'activateur du plasminogene du tissu humain. | |
NO870772L (no) | Vevplasminogenaktivator for normale humane tykktarmceller. | |
ES2184145T3 (es) | Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida. | |
BRPI0418157A (pt) | terapêutica de tumores alogênicos | |
DE69625918D1 (de) | Lang wirksames mittel zur rektalen verabreichung | |
ES2180729T3 (es) | Tratamiento terapeutico combinado de las patologias hiperproliferantes. | |
DOP2002000369A (es) | Composicion | |
ES2172558T3 (es) | Lubricante compatible con radiaciones para dispositivos medicos. |